-

Metagenomi to Present at the Chardan 2022 Metagenomics and Microbiome Medicines Summit

EMERYVILLE, Calif.--(BUSINESS WIRE)--Metagenomi, a genetic medicines company with a versatile portfolio of next-generation gene editing tools, today announced that Brian C. Thomas, PhD, Founder and CEO of Metagenomi, and Chris Brown, PhD, Senior Director of Discovery, will present at the virtual Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1, 2022.

Chardan 2022 Metagenomics and Microbiome Medicines Summit
Date: Tuesday, March 1, 2022
Presentation Time: 11:45 a.m. ET

About Metagenomi

Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific and have a decreased risk of immune response. These systems fuel our pipeline of novel medicines and can be leveraged by partners. Our goal is to revolutionize gene editing for the benefit of patients around the world. For more information, please visit https://metagenomi.co/.

Contacts

Investor:
Simon Harnest
CIO, SVP Strategy
simon@metagenomi.co
(917) 403-1051

Media:
Ashlye Hodge
Sr. Marketing and Communications Specialist
ashlye@metagenomi.co
(510) 734-4409

Industry:

Metagenomi

Release Versions
English

Contacts

Investor:
Simon Harnest
CIO, SVP Strategy
simon@metagenomi.co
(917) 403-1051

Media:
Ashlye Hodge
Sr. Marketing and Communications Specialist
ashlye@metagenomi.co
(510) 734-4409

More News From Metagenomi

Affini-T Therapeutics & Metagenomi Announce Next-Generation Gene Editing Partnership to Advance Cell Therapies for Solid Tumor Patients

BOSTON & SEATTLE & EMERYVILLE, Calif.--(BUSINESS WIRE)--Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, and Metagenomi, Inc., a genetic medicines company with a versatile portfolio of next-generation, wholly-owned gene editing tools, today announced a partnership to enable Affini-T’s next generation ex vivo T cell receptor (TCR) cell therapies for solid tumor patients using Metagenomi’s novel proprietary gene editing system...

Metagenomi Presents New Preclinical Data at ASGCT on Proprietary, Highly Efficient CRISPR Gene Editing Systems and a Novel Family of CRISPR-Associated Transposases (CASTs)

EMERYVILLE, Calif.--(BUSINESS WIRE)--Metagenomi, a genetic medicines company with a versatile portfolio of wholly-owned, next-generation gene editing tools, today presented new preclinical data on proprietary CRISPR-associated systems that have the potential to be used in the development of cell therapy and a novel family of CRISPR-associated transposases (CASTs) at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting. The first presentation demonstrates that Metagenomi’s g...

Metagenomi to Present New Preclinical Data at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

EMERYVILLE, Calif.--(BUSINESS WIRE)--Metagenomi today announced that two presentations will be made at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting....
Back to Newsroom